Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, Irvine
Mayo Clinic
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Thomas Jefferson University
University of Southern California
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Ankyra Therapeutics, Inc
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
Sanofi
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
BioNTech SE
OncoNano Medicine, Inc.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
University of Pittsburgh
Regeneron Pharmaceuticals
H. Lee Moffitt Cancer Center and Research Institute
University of Southern California
Bolt Biotherapeutics, Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Vyriad, Inc.
OncoResponse, Inc.
University of Zurich
OncoResponse, Inc.
Jules Bordet Institute
Exicure, Inc.
Oncovir, Inc.
Regeneron Pharmaceuticals